

Melanoma & Merkel Cell Carcinoma Requisition to PET Centre

TO BE COMPLETED BY THE REFERRING PHYSICIAN

The indications under Section B are part of the Ontario PET Registry. Completion of a post scan form is required following the PET scan. Together the pre and post scan information will provide vital data to build evidence for use of PET for this indication. Accurately complete both the pre and post scan forms.

Referring Physician Name: _____			
Physician Phone: (_____)		ext. _____	Fax: (_____)
CPSO No: _____			
Patient Name: _____			
SURNAME		FIRST NAME	MIDDLE
OHIP Number: _____			
Telephone: (_____)		Postal Code: _____	
Date of birth: _____ / _____ / _____		Gender: <input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Other	
YYYY		MM / DD	

Relevant Clinical History:

Provide the most recent and relevant imaging report(s) and other relevant clinical history.

The following documents must be attached to this requisition:

- Relevant Imaging Studies within the previous 3 months (i.e. CT, US, MR, Other)
- Consult Note or Referral Letter; including relevant lab work/pathology, if relevant

Fax Instructions

Please fax the completed request form, along with the required supporting documentation, to the PET Centre of choice for appointment. A complete list of PET Centres and their contact information is available at [PET Scan Services in Ontario](#)

Complete EITHER Section A or B (not both)

Section A – PET for the staging of patients with localized “high risk” melanoma OR Merkel Cell Carcinoma, or for the evaluation of patients with isolated metastases, when surgery or other ablative therapies are being considered.

Indication (choose only one)

- Staging of:
 - Localized high risk melanoma, OR
 - Merkel Cell Carcinoma(e.g., lymph node metastases, satellitosis or intransit metastases, or deep head & neck melanoma)
- Evaluation of isolated metastases

Attach the relevant diagnostic imaging reports (CT, US, MRI) & provide images to PET centre.

Physician Signature: _____ Date: _____

Version Date: April 4th, 2025

*PET Centre Use Only: Registry Indication – PET Centre must submit pre- & post-scan forms to OH to be eligible for funding
Need this information in an accessible format? 1-877-280-8538, TTY 1-800-855-0511, info@ontariohealth.ca
Document disponible en français en contactant info@ontariohealth.ca

Melanoma & Merkel Cell Carcinoma Requisition to PET Centre

TO BE COMPLETED BY THE REFERRING PHYSICIAN

Complete EITHER Section A or B (not both)

Patient Name: _____

***Section B – PET in Immunotherapy for Metastatic Melanoma OR Merkel Cell Carcinoma**

Melanoma

Type of Melanoma:

- Cutaneous Mucosal Acral Lentiginous
 Uveal Unknown Primary

BRAF Status (Melanoma only):

- Wild Type Mutant
 Other molecular change (specify): _____

Current line of Immunotherapy:

- First Line Second Line Other (specify): _____

Has the patient received prior adjuvant immunotherapy?

- Yes No

Merkel Cell Carcinoma:

Primary Location of Merkel cell carcinoma:

- Head & Neck Trunk Extremity Mucosal
 Unknown Other (specify): _____

Polyomavirus IHC:

- Present Absent Unknown

Current line of Immunotherapy:

- First Line Second Line Other (specify): _____

Has the patient received prior adjuvant immunotherapy?

- Yes No

Has the patient received prior chemotherapy?

- Yes No

Indication (choose only one)

- *Baseline Staging – PET for the baseline staging of patients with metastatic melanoma OR Merkel Cell Carcinoma prior to starting immunotherapy; or for patients who are receiving immunotherapy and have not previously had a baseline PET.**
 (choose one)

- Baseline PET **PRIOR** to patients starting immunotherapy

- Baseline PET for patients who are receiving immunotherapy, and have not previously had a Baseline PET

- *Response Assessment – PET for response assessment of patients with metastatic melanoma OR Merkel Cell Carcinoma currently receiving immunotherapy.**

Reason for PET: Early Response Assessment (choose one): After 2 cycles After 3 cycles After 4 cycles

- Other (specify): after _____ cycles (Merkel Cell Carcinoma only)

End of Therapy Response Assessment (specify reason):

- Therapy Complete Adverse Event Patient Decision

- Radiographic Complete Response or Good Partial Response

- Other (specify): _____

Immunotherapy Start Date: _____
YYYY-MM-DD

Date of most recent Immunotherapy dose: _____
YYYY-MM-DD

Current Immunotherapy Regimen (select all that apply):

- Anti PD1 Monotherapy Anti CTLA-4 Monotherapy Anti PD1 & Anti CTLA-4 combination therapy

- Anti PDL1 Monotherapy

- Other (specify): _____

Melanoma & Merkel Cell Carcinoma Requisition to PET Centre
TO BE COMPLETED BY THE REFERRING PHYSICIAN

Complete EITHER Section A or B (not both)

Patient Name: _____

***Section B (continued) – PET in Immunotherapy for Metastatic Melanoma OR Merkel Cell Carcinoma**

Baseline PET scan available for comparison? No Yes (specify date): _____
YYYY-MM-DD

Residual Lesion(s) on CT?

Not Applicable (no CT available)

No

Yes (specify total number & locations): Number of lesions: 1 2 3 ≥ 4

Location of lesions: Lung Liver Bone Adrenal Brain

Other (specify): _____

Does patient have clinical evidence of immune related adverse event(s)?

No

Yes (select all that apply): Enterocolitis Fatigue Hematological Hepatitis Hypophysitis

Pancreatitis Rash Pneumonitis Peripheral neuropathy

Sarcoidosis Thyroiditis Other (specify): _____

Select Management Plan – if PET were NOT available, what is your Current Management Plan

Pre-PET Treatment Plan (select all that apply):

Start Immunotherapy (specify):

Anti PD1 Monotherapy

Anti PD1 & Anti CTLA-4 combination therapy

Anti CTLA-4 Monotherapy

Other (specify): _____

Continue Immunotherapy

Discontinue Immunotherapy

Surgery

Targeted Therapy

Clinical Trial, (specify the protocol or SOC Name or Number): _____

Radiation

Chemotherapy, (specify both regimen & number of cycles): a. Regimen _____

b. Number of Cycles: _____

Other, please describe _____

Physician Signature: _____ **Date:** _____